Abstract Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab,
represent the latest class of biologics approved for the treatment of moderate-to-severe …

Subclinical inflammation is associated with Spondylarthritis (SpA). SpA patients show
features of dysbiosis, altered gut barrier function, and local expansion of innate and innate …

Introduction The benefit/risk profiles of biologics can be affected by comorbidities, certain
demographic characteristics, and concomitant medications; therefore, it is important to …

The three monoclonal antibodies ustekinumab, guselkumab and risankizumab targeting the
p 40 or the 19 subunit of interleukin-23 have now been approved for the indication psoriasis …

Introduction The aim of this work is to evaluate treatment persistence and clinical outcomes
after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active …

Background Psoriasis and psoriatic arthritis are chronic inflammatory skin and joint diseases
requiring effective therapies. Although clinical studies have shown the efficacy of IL‐23 …

ABSTRACT Introduction Psoriatic arthritis (PsA) is a chronic arthritis typically associated with
cutaneous psoriasis (PsO). Its pathogenesis is connected to an innate and acquired immune …

Objectives To evaluate the efficacy of guselkumab for the treatment of active PsA utilizing
composite indices. Methods Data were pooled from the phase 3 DISCOVER-1 (n= 381) and …

Background The monoclonal antibody guselkumab is the first selective inhibitor of the
interleukin-23 p19 subunit approved to treat adults with moderate-to-severe plaque …

Guselkumab is a monoclonal antibody that selectively blocks the p19 subunit of interleukin
23 and has been approved for the treatment of moderate to severe psoriasis and active …